Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem

Metabol Open. 2021 Jun:10:100089. doi: 10.1016/j.metop.2021.100089. Epub 2021 Mar 24.
No abstract available

Keywords: Cardiovascular disease; Diabetes; Heart failure; Sodium glucose co-transporters inhibitor; Sotagliflozin.

Publication types

  • Editorial